Publications

2025

Higgins, V., Beriault, D., Parker, M., Bhayana, V., Booth, R., Chen, Y., ... & Thebault, S. (2025). B-102 Harmonizing cerebrospinal fluid analysis for multiple sclerosis investigation: An update from the hCAMI subcommittee of the Canadian Society of Clinical Chemists (CSCC). Clinical Chemistry, 71(Supplement_1), hvaf086-500.

Bigotte, M., Groh, A. M., Afanasiev, E., Wong, V., Lancon, K., Yaqubi, M., ..Thebault, S., & Stratton, J. A. (2025). Cerebrospinal fluid-driven ependymal motile cilia defects are implicated in multiple sclerosis pathophysiology. bioRxiv, 2025-07.

Abdelhak, A., Bachhuber, F., Ning, K., Benkert, P., Boscardin, W. J., Maceski, A. M., ...Thebault, S.,.. & Tumani, H. (2025). Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis. Journal of Neurology, Neurosurgery & Psychiatry.

Espinoza, D. A., Zrzavy, T., Breville, G., Thebault, S., Marefi, A., Mexhitaj, I., ... & Bar-Or, A. (2025). Pediatric cerebrospinal fluid immune profiling distinguishes pediatric-onset multiple sclerosis from other pediatric-onset acute neurological disorders. bioRxiv.

Spangler, B. C., Jacobs, P. S., Horwath, E. A., Yamashita, L., Thebault, S., Bar-Or, A., ... & Schindler, M. (2025, May). Higher GluCEST Contrast Observed in Paramagnetic Rim Lesions than Quiescent MS Lesions: Elucidating the Role of Glutamate in Chronic Inflammation. In MULTIPLE SCLEROSIS JOURNAL (Vol. 31, No. 2_ SUPPL, pp. 244-244). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Thebault, S., Soldan, S. S., Breville, G., Yamashita, L. D., Kim, Y., MacMullen, L. N., ... & Bar-Or, A. (2025, May). Elevated EBV Viral Loads and Lytic Transcripts Are Associated With MRI Activity in MS: Cross-Sectional and Longitudinal Comparisons. In MULTIPLE SCLEROSIS JOURNAL (Vol. 31, No. 2_ SUPPL, pp. 244-244). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Thebault, S., Breville, G., Yamashita, L. D., Spangler, B. C., Mcgoldrick, T., Jefferson, A., ... & Schindler, M. K. (2025, May). PRL Burden is Associated with CSF and Blood Immune Cell Measures Indicative of Compartmentalized Inflammation in MS. In MULTIPLE SCLEROSIS JOURNAL (Vol. 31, No. 2_ SUPPL, pp. 23-23). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Kanaan, Z., Nguyen-Tran, T., Sherman, S., Thebault, S., Atkins, H., Freedman, M. S., ... & Fadda, G. (2025, May). Reversing Pro-Inflammatory Lipidomic Profiles Following Autologous Hematopoietic Stem Cell Transplantation Treatment For Multiple Sclerosis. In MULTIPLE SCLEROSIS JOURNAL (Vol. 31, No. 2_ SUPPL, pp. 244-244). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Thebault, S. (2025). Blood-Based Biomarkers in Neurology: Harnessing the Potential of Neurofilament Light Chain in Relapsing Multiple Sclerosis. Neurology.

Bose, G., Thebault, S. D., Fadda, G., Brooks, J. A., & Freedman, M. S. (2025). Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions. Neurotherapeutics, e00588.

Labib, M., Thebault, S., Booth, R. A., Brooks, J., Rush, C., MacLean, H., ... & Fadda, G. (2025). The utility of serum neurofilament light chain in MOGAD: Current insights and future directions. Multiple Sclerosis and Related Disorders, 106410.

2024

Wurtz, L. I., Knyazhanskaya, E., Sohaei, D., Prassas, I., Pittock, S., Willrich, M. A. V., Thebault, S.,... & Scarisbrick, I. A. (2024). Identification of brain-enriched proteins in CSF as biomarkers of relapsing remitting multiple sclerosis. Clinical Proteomics, 21(1), 42.

Thebault, S., Fereshtehnejad, S. M., Bergman, H. P., Breville, G., Abdoli, M., Booth, R. A., ... & Bose, G. (2024). The combination of CSF neurofilament light chain and glial fibrillary acidic protein improves the prediction of long-term confirmed disability worsening in multiple sclerosis. Scientific Reports, 14(1), 29135.

Reilly, A., Beauvais, A., Al-Aarg, M., Yaworski, R., Sutton, E. R., Thebault, S., & Kothary, R. (2024). Peripheral defects precede neuromuscular pathology in the Smn2B/− mouse model of spinal muscular atrophy. Journal of Neuromuscular Diseases, 11(6), 1200-1210.

Thebault, S., Soldan, S., Breville, G., Dowling, J., Schindler, M., Yamashita, L., ... & Bar-Or, A. (2024, September). Elevated EBV viral loads and dysregulated lytic/latent profiles in blood and CSF B cells of MS patients compared to neuroinflammatory disease controls. In MULTIPLE SCLEROSIS JOURNAL (Vol. 30, No. 3, pp. 9-9). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Soldan, S. S., Su, C., Monaco, M. C., Yoon, L., Kannan, T., Zankharia, U., Thebault, S.,... & Lieberman, P. M. (2024). Multiple sclerosis patient-derived spontaneous B cells have distinct EBV and host gene expression profiles in active disease. Nature microbiology, 9(6), 1540-1554.

Khalil, M., Teunissen, C. E., Lehmann, S., Otto, M., Piehl, F., Ziemssen, T., Thebault, S.,... & Kuhle, J. (2024). Neurofilaments as biomarkers in neurological disorders—towards clinical application. Nature Reviews Neurology, 20(5), 269-287.

Cross, A. H., Gelfand, J. M., Thebault, S., Bennett, J. L., Von Büdingen, H. C., Cameron, B., ... & Bar-Or, A. (2024). Emerging cerebrospinal fluid biomarkers of disease activity and progression in multiple sclerosis. JAMA neurology, 81(4), 373-383.

Wilson, D., Chan, D., Chang, L., Mathis, R., Verberk, I., Montalban, X., Thebault, S., ... & Kuhle, J. (2024). Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury. Clinical Chemistry and Laboratory Medicine (CCLM), 62(2), 322-331.

2023

Sohaei, D., Thebault, S., Avery, L. M., Batruch, I., Lam, B., Xu, W., ... & Freedman, M. S. (2023). Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis. Clinical Proteomics, 20(1), 33.

Hamwi, M., Thebault, S., Melkus, G., Auriat, A. M., Pham, A., Carrington, A., ... & Aviv, R. I. (2023). MRI graph parameters are longitudinal markers of neuronal integrity in multiple sclerosis. Multiple Sclerosis and Related Disorders, 80, 105066.

Sy, A., Thebault, S., Aviv, R. I., & Auriat, A. M. (2023). An overview of transcranial magnetic stimulation and its application in multiple sclerosis. Applied Sciences, 13(23), 12679.

Thebault, S., Bose, G., Fadda, G., Freedman, M. S., & Booth, R. (2023, October). Reference change values of longitudinal sNfL to detect subclinical disease activity in individual patients with MS. In Multiple Sclerosis Journal (Vol. 29, pp. 1076-1077). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Rezk, A., Li, R., Breville, G., Thebault, S., Fraser, J. L., Tochen, L., ... & Orthmann-Murphy, J. (2023, September). Identification of Unique Peripheral Monocyte Phenotypes in CSF1R-Related Leukoencephalopathies. In ANNALS OF NEUROLOGY (Vol. 94, pp. S217-S217). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.

Thebault, S., Bar-Or, A., & Banwell, B. (2023). NfL is ready for translation into paediatrics. The Lancet Neurology, 22(9), 774-776.

Ulndreaj, A., Sohaei, D., Thebault, S., Pons-Belda, O. D., Fernandez-Uriarte, A., Campbell, C., ... & Diamandis, E. P. (2023). Quantitation of neurofilament light chain protein in serum and cerebrospinal fluid from patients with multiple sclerosis using the MSD R-PLEX NfL assay. Diagnosis, 10(3), 275-280.

Thebault, S., Gandelman, S., Lane, C., Kim, E. J., Pileggi, C., Zuroff, L., ... & Jacobs, D. A. (2023). Severe neuroinvasive West Nile virus in association with anti-CD20 monotherapy for multiple sclerosis. Neurology: Neuroimmunology & Neuroinflammation, 10(5), e200154.

Gandelman, S. B., Thebault, S., Zuroff, L., Pileggi, C., Markowitz, C. E., Brandstadter, R., & Jacobs, D. A. (2023, May). Neuroinvasive West Nile Virus in Association with Ocrelizumab Use in Multiple Sclerosis. In MULTIPLE SCLEROSIS JOURNAL (Vol. 29, pp. 96-96). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Saldivar-Davila, S., Thebault, S., Rush, C., Maclean, H., Brooks, J., Bose, G., & Freedman, M. S. (2023, May). Inability to Reduce CD-20 Cells Has No Apparent Impact on Clinical, Laboratory or Radiological Activity Among Patients Receiving Ocrelizumab. In MULTIPLE SCLEROSIS JOURNAL (Vol. 29, pp. 29-30). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Thebault, S., Saldivar-Davila, S., Bose, G., Freedman, M. S., & Booth, R. A. (2023, May). Reference Change Values of Longitudinal sNfL Measurements can be Used to Detect New Disease Activity in MS at the Individual Patient Level. In MULTIPLE SCLEROSIS JOURNAL (Vol. 29, pp. 35-36). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Meier, S., Benkert, P., Maceski, A. M., Schaedelin, S., Oechtering, J., Melie-Garcia, L., Thebault, S.,... & Kuhle, J. (2023). Serum Glial Fibrillary Acidic Protein compared with Neurofilament Light Chain as Biomarker for Multiple Sclerosis Disease Progression (P5-3.016). Neurology, 100(17_supplement_2), 3113.

Thebault, S., Fereshtehnejad, S. M., Bergman, H., Bose, G., & Freedman, M. (2023). Serum neurofilament light chain (NfL) and CSF glial fibrillary acidic protein (GFAP) together improve the prediction of long-term clinical outcomes in multiple sclerosis (S9. 001). Neurology, 100(17_supplement_2), 2065.

Meier, S., Willemse, E. A., Schaedelin, S., Oechtering, J., Lorscheider, J., Melie-Garcia, L.,Thebault, S., ... & Kuhle, J. (2023). Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA neurology, 80(3), 287-297.

2022

Thebault, S., Warman-Chardon, J., O'Connell, K., Miller, W. D., & Bourque, P. R. (2022). Isolated Internuclear Ophthalmoplegia as an Embolic Complication of Transcatheter Aortic Valve Implantation. Cureus, 14(12).

Thebault, S., Bergman, H., Atkins, H. L., Freedman, M. S., & Brooks, J. (2022). CLIPPERS responsive to cladribine as a durable steroid-sparing agent. Neurology: Neuroimmunology & Neuroinflammation, 10(1), e200060.

Thebault, S., Fereshtehnejad, S. M., Bose, G., Abdoli, M., & Freedman, M. S. (2022, October). Combining levels of serum neurofilament light chain with CSF glial fibrillary acidic protein improves the prediction of long-termclinical outcomes in multiple sclerosis. In MULTIPLE SCLEROSIS JOURNAL (Vol. 28, No. 3_ SUPPL, pp. 960-960). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Reilly, A., Deguise, M. O., Beauvais, A., Yaworski, R., Thebault, S., Tessier, D. R., ... & Kothary, R. (2022). Central and peripheral delivered AAV9-SMN are both efficient but target different pathomechanisms in a mouse model of spinal muscular atrophy. Gene Therapy, 29(9), 544-554.

Thebault, S., Bose, G., Booth, R., & Freedman, M. S. (2022). Serum neurofilament light in MS: The first true blood-based biomarker?. Multiple Sclerosis Journal, 28(10), 1491-1497.

Thebault, S., Hamwi, M., Melkus, G., Berard, J., Lymer, J. M., Freedman, M. S., ... & Aviv, R. I. (2022, May). Longitudinal comparison of MRI graph parameter measures of functional connectivity and cognition in patients with MS. In MULTIPLE SCLEROSIS JOURNAL (Vol. 28, No. 1_ SUPPL, pp. 165-165). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Brunet, F., Freedman, M., Puyade, M., Atkins, H., Rush, C., & Thebault, S. (2022, May). Autologous Hematopoietic Stem Cell Transplantation in patients with Multiple Sclerosis: Long term follow up of the Ottawa cohort. In MULTIPLE SCLEROSIS JOURNAL (Vol. 28, No. 1_ SUPPL, pp. 8-8). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Thebault, S., Melkus, G., Hamwi, M., Brunet, F., Freedman, M., Aviv, R. I., & Tremblay, F. (2022, May). Non-invasive biomarkers of upper limb motor function: correlations between MRI network parameters and transcranial magnetic stimulation measures. In MULTIPLE SCLEROSIS JOURNAL (Vol. 28, No. 1_ SUPPL, pp. 41-42). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Thebault, S., Brunet, F., Brooks, J., Maclean, H., Rush, C., Freedman, C., ... & Freedman, M. (2022, May). Longitudinal increases in serum GFAP but not NfL associate with longitudinal worsening in clinical and electrophysiologic makers of motor function in MS. In MULTIPLE SCLEROSIS JOURNAL (Vol. 28, No. 1_ SUPPL, pp. 37-38). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Sohaei, D., Thebault, S., Avery, L., Scarisbrick, I. A., Diamandis, E., Freedman, M., & Prassas, I. (2022, May). Baseline Calcium/Calmodulin Dependent Protein Kinase II Alpha levels in CSF inform 15-year clinical outcomes in multiple sclerosis. In MULTIPLE SCLEROSIS JOURNAL (Vol. 28, No. 1_ SUPPL, pp. 24-24). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Hamwi, M., Thebault, S., Melkus, G., Walker, L., Chakraborty, S., Torres, C., ... & Freedman, M. S. (2022, May). MRI graph parameters as longitudinal markers of neuron integrity in MS. In MULTIPLE SCLEROSIS JOURNAL (Vol. 28, No. 1_ SUPPL, pp. 38-38). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Sohaei, D., Thebault, S., Avery, L., Prassas, I., Soosaipillai, A., Freedman, M., & Diamandis, E. (2022, May). Immuno-mass spectrometric identification of autoantibodies in cerebrospinal fluid of multiple sclerosis patients. In MULTIPLE SCLEROSIS JOURNAL (Vol. 28, No. 1_ SUPPL, pp. 35-35). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Berard, J. A., Freedman, M. S., Marrie, R. A., Marriott, J. J., Atkins, H. L., Szwajcer, D., Thebault, S.,... & Walker, L. A. (2022). Mesenchymal stem cell therapy and cognition in MS: preliminary findings from a phase II clinical trial. Multiple sclerosis and related disorders, 61, 103779.

Thebault, S., Kim, W., Hadwen, J., Walker, G. B., Drake, B., & Fantaneanu, T. A. (2022). Progressive Myelopathy With Acute Worsening After Steroids and Lumbar Puncture. The Neurohospitalist, 12(2), 318-322.

Thebault, S., Reaume, M., Marrie, R. A., Marriott, J. J., Furlan, R., Laroni, A., ... & Freedman, M. S. (2022). High or increasing serum NfL is predictive of impending multiple sclerosis relapses. Multiple sclerosis and related disorders, 59, 103535.

2021

Thebault, S., Gibbs, E., Bourque, P., McKim, D., Rakhra, K., Breiner, A., ... & Warman-Chardon, J. (2021). MuSK not MNGIE: Atypical MuSK-antibody myasthenia presenting as a genetic disorder. Neuromuscular Disorders, 31(12), 1279-1281.

Reilly, A., Deguise, M. O., Beauvais, A., Yaworski, R., Thebault, S., Tessier, D. R., ... & Kothary, R. (2021). Central and peripheral delivery of AAV9-SMN target different pathomechanisms in a mouse model of spinal muscular atrophy. bioRxiv, 2021-11.

Melkus, G., Hamwi, M., Thebault, S., Walker, L., Chakraborty, S., Torres, C., ... & Freedman, M. S. (2021). P. 139 Random Neural Network Features in Patients with Aggressive Multiple Sclerosis Undergoing Autologous Hematopoietic Stem Cell Transplant. Canadian Journal of Neurological Sciences, 48(s3), S59-S59.

Abdoli, M., Thebault, S., Freedman, M. S., Tessier, D., Tobbard-Cossa, V., & Fereshtehnejad, S. M. (2021). P. 043 Long term MS clinical outcomes predicted by baseline serum neurofilament light levels. Canadian Journal of Neurological Sciences, 48(s3), S32-S32.

Thebault, S., Mariott, J., Marrie, R. A., Laroni, A., Uccelli, A., & Freedman, M. (2021, October). Serum neurofilament and GFAP remain elevated in MS patients following mesenchymal stem cell transplantation for multiple sclerosis. In MULTIPLE SCLEROSIS JOURNAL (Vol. 27, No. 2_ SUPPL, pp. 518-519). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Thebault, S., Reaume, M., Booth, R., & Freedman, M. (2021, October). High or increasing serum NfL predicts impending multiple sclerosis relapses. In MULTIPLE SCLEROSIS JOURNAL (Vol. 27, No. 2_ SUPPL, pp. 506-507). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Hamwi, M., Melkus, G., Thebault, S., Walker, L., Chakraborty, S., Torres, C., ... & Freedman, M. S. (2021, June). Random Neural Network Features in Patients with Aggressive Multiple Sclerosis Undergoing Autologous Hematopoietic Stem Cell Transplant. In MULTIPLE SCLEROSIS JOURNAL (Vol. 27, No. 1_ SUPPL, pp. 18-18). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Thebault, S., Booth, R. A., Rush, C. A., MacLean, H., & Freedman, M. S. (2021). Serum neurofilament light chain measurement in MS: hurdles to clinical translation. Frontiers in Neuroscience, 15, 654942.

Bose, G., Thebault, S., Rush, C. A., Atkins, H. L., & Freedman, M. S. (2021). Autologous hematopoietic stem cell transplantation for multiple sclerosis: a current perspective. Multiple Sclerosis Journal, 27(2), 167-173.

2020

Thebault, S., Fereshtehnejad, S. M., Laforte, V., Freedman, M., Juncker, D., & Bar-Or, A. (2020, December). Longitudinal proteomic analysis of ms patients before and after autologous hematopoietic stem cell transplantation. In MULTIPLE SCLEROSIS JOURNAL (Vol. 26, No. 3_ SUPPL, pp. 169-169). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Thebault, S., Abdoli, M., Fereshtehnejad, S. M., Tessier, D., Tabard-Cossa, V., & Freedman, M. (2020, December). Comparison of serum and csf fluid biomarkers for predicting long term disease progression in ms. In MULTIPLE SCLEROSIS JOURNAL (Vol. 26, No. 3_ SUPPL, pp. 142-142). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Sohaei, D., Thebault, S., Batruch, I., Prassas, I., Freedman, M., & Diamandis, E. (2020, December). Identification of putative multiple sclerosis biomarkers in csf by targeted-mass spectrometry. In MULTIPLE SCLEROSIS JOURNAL (Vol. 26, No. 3_ SUPPL, pp. 160-161). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Thebault, S., Booth, R. A., & Freedman, M. S. (2020). Blood neurofilament light chain: the neurologist’s troponin?. Biomedicines, 8(11), 523.

Thebault, S., Abdoli, M., Fereshtehnejad, S. M., Tessier, D., Tabard-Cossa, V., & Freedman, M. S. (2020). Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis. Scientific reports, 10(1), 10381.

Thebault, S., Abdoli, M., Fereshtehnejad, S., Tessier, D., Tabard-Cossa, V., & Freedman, M. S. (2020, May). Can We Predict Long-Term MS Outcomes With A Blood Test?. In MULTIPLE SCLEROSIS JOURNAL (Vol. 26, No. 1_ SUPPL, pp. 18-18). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Thebault, S., Lee, H., Bose, G., Tessier, D., Abdoli, M., Bowman, M., ... & Freedman, M. S. (2020). Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis. Annals of Clinical and Translational Neurology, 7(5), 767-775.

Thebault, S., Abdoli, M., Fereshtehnejad, S. M., Tessier, D., Tabard-Cossa, V., & Freedman, M. (2020). Serum Neurofilament Light Chain Predicts Long-term Clinical Outcomes in Multiple Sclerosis (130). Neurology, 94(15_supplement), 130.

Thebault, S., Booth, R. A., & Freedman, M. S. (2020). Blood neurofilament light chain: the Neurologist’s Troponin? Biomedicines 8 (11): 523.

Bose, G., Thebault, S. D., Atkins, H. L., & Freedman, M. S. (2020). Does resetting the immune system fix multiple sclerosis?. Canadian Journal of Neurological Sciences, 47(1), 1-10.

2019

Thebault, S., R. Tessier, D., Lee, H., Bowman, M., Bar-Or, A., Arnold, D. L., ... & Freedman, M. S. (2019). High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS. Neurology: Neuroimmunology & Neuroinflammation, 6(5), e598.

Brooks, J., Atkins, H., Bose, G., Thebault, S., Freedman, M., & Rush, C. (2019, September). Autologous hematopoietic stem cell transplant in patients with severe refractory neuromyelitis optica spectrum disease: the Ottawa experience. In Multiple Sclerosis Journal (Vol. 25, pp. 46-47). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Abdoli, M., Thebault, S., Freedman, M. S., Fereshtehnejad, S. M., Tabard-Cossa, V., & Tessier, D. R. (2019, September). Long term MS clinical outcomes predicted by baseline serum neurofilament light levels. In MULTIPLE SCLEROSIS JOURNAL (Vol. 25, pp. 506-507). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD.

Thebault, S., Lee, H., Tessier, D., Bowman, M., Bar-Or, A., Arnold, D., ... & Freedman, M. (2019). A. 02 Serum biomarkers of MS disease activity in patients treated with bone marrow transplant. Canadian Journal of Neurological Sciences, 46(s1), S8-S8.

Thebault, S., Tessier, D., Bowman, M., Lee, H., Arnold, D., Bar-Or, A., ... & Freedman, M. (2019). Serum Neurofilamant, GFAP and Tau in Patients with Aggressive Multiple Sclerosis Before and After Haematopoietic Stem Cell Transplant (S37. 004). Neurology, 92(15_supplement), S37-004.

Thebault, S., Tessier, D., Bowman, M., Lee, H., Arnold, D. L., Tabard-Cossa, V., & Freedman, M. S. (2019, February). Serum Biomarkers Following Autologous Haematopoetic Stem Cell Transplant for Aggressive MS. In ACTRIMS Forum 2019. ACTRIMS.

Thebault, S., D RT, L. H., Bowman, M., Bar-Or, A., Arnold, D. L., H LA, T. C. V., & Freedman, M. S. (2019). High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS. Neurol Neuroimmunol Neuroinflamm 6 (5).

Page updated

Google Sites

Report abuse